Aphthous Stomatitis

Back

Background

Aphthous stomatitis, also known as recurrent aphthous ulcers or canker sores, is among the most common oral mucosal lesion physicians and dentists observe. Aphthous stomatitis is a disorder of unknown etiology that may cause significant morbidity. One or several discrete, shallow, painful ulcers are visible on the unattached oral mucous membranes. Individual ulcers typically last 7-10 days and heal without scarring. Larger ulcers may last several weeks to months and can scar when healing.

Pathophysiology

Although the process in idiopathic recurrent aphthous ulcers is usually self-limiting, in some individuals, ulcer activity can be almost continuous. Similar ulcers can be noted in the genital region. Behçet syndrome, systemic lupus erythematosus, and inflammatory bowel disease are systemic diseases associated with oral recurrent aphthous ulcers.

Recurrent aphthous ulcers occur on nonkeratinized or poorly keratinized surfaces of the mucosa such as following:

The clinical presentation of aphthous ulcers is defined by the number of recurrences and severity of disease. Clinically, the number and size of the ulcers are the two main criteria used to divide ulcers into three forms: minor, major, and herpetiform. Simple aphthae are common and considered mild, with 1-4 episodes per year. In general, there are few lesions of the minor or herpetiform form. In contrast, complex aphthosis has a severe clinical course, with an almost continuous presence of minor or major ulcers. These may be debilitating and may also involve the genitalia of both men and women. It is imperative that these patients be evaluated to rule out Behçet disease as well as inflammatory bowel disease.

Recurrent aphthous ulcer minor (Mikulicz ulcer)

This is the most common form, accounting for 80-85% of cases. Discrete, painful, shallow, recurrent ulcers smaller than 1 cm in diameter characterize this form, shown in the image below. At any time, one or multiple ulcers can be manifest. These ulcers heal within 7-14 days without scarring. The periodicity varies among individuals, with some having long ulcer-free episodes and some never being free from ulcers.



View Image

Minor aphthous ulcer: Small superficial oval erosions with yellow pseudomembrane and an erythematous border are evident on the labial aspect of the le....

Recurrent aphthous ulcer major (Sutton ulcer, periadenitis mucosa necrotica recurrens)

This form accounts for about 5-10% of cases and present as round or oval ulcers that range in size from 2-3 cm in diameter, as shown in the image below. Major aphthae typically present as a single ulcer, but multiple ulcers may occur. The ulcers present on the soft palate, lips, or oropharynx. They may be deep with smooth or irregular borders. The ulcers may coalesce. Healing, which may take 6 weeks or even months, results in scarring; severe distortion of oral and pharyngeal mucosa may occur. These are more common in patients with HIV disease.



View Image

Major aphthous ulcer: Large oval ulcer with white pseudomembrane and raised red border located on the right upper labial mucosa adjacent to the buccal....

Herpetiform recurrent aphthous ulcer

In this rare form (<5% of cases), ulcers are typically about 1-2 mm in diameter. The aphthae tend to occur in clusters or crops consisting of 10-100 ulcers. Clusters may be small and localized, or they may be distributed throughout the soft mucosa of the oral cavity. These too occur predominantly on unkeratinized mucosa, as shown in the image below. It is important to differentiate these ulcers from herpes simplex virus (HSV), which also may appear as recurrent crops. HSV is an infectious disease that often presents with vesicles that quickly ulcerate and involve the keratinized mucosa of the hard palate, dorsal tongue and attached gingiva.



View Image

Herpetiform aphthous ulcer: Grouped and single tiny white to yellow ulcers scattered on the labial mucosa and on the ventral aspect of the tongue.

Epidemiology

US frequency

Recurrent aphthous ulcers are the most common oral mucosal disease in North America. They affect 20% of the population, with the incidence rising to more than 50% in certain groups of students in professional schools. Children from high socioeconomic groups may be affected more than those from low socioeconomic groups.[1] Note the following point prevalence and lifetime prevalence rates[2] :

International frequency

Recurrent aphthous ulcers occur worldwide and are reported on every populated continent. Recurrent aphthous ulcers affect 2-66% of the international population.[3] . Epidemiologic studies have been conducted in various subpopulations and report data on both point prevalence and lifetime prevalence, as follows:

Sex

In children and in some adult communities who are affected, the incidence of recurrent aphthous ulcer is higher in women and girls than in men or boys.[4]

Age

Recurrent aphthous ulcer minor is the most common form of childhood recurrent aphthous ulcer. Approximately 1% of American children may have recurrent aphthous ulcers, with onset before age 5 years. The percentage of patients who are affected decreases after the third decade.[14]

Recurrent aphthous ulcer major has a typical onset after puberty and can persist for the remainder of an individual's life, although after late adulthood episodes become much less common.[14]

Herpetiform recurrent aphthous ulcer first occurs in the second decade of life; the majority of persons have onset when younger than 30 years. The frequency and the severity of episodes may increase during the third and fourth decades and then decrease with advancing age.[14]

Patient Education

For patient education resources, visit the Oral Health Center. Also, see the patient education article Canker Sores.

History

Recurrent aphthous ulcers consist of one or multiple round-to-ovoid, shallow, punched-out–appearing, painful oral ulcers that recur at intervals of a few days to a few months. To evaluate oral ulcers as recurrent aphthous ulcers, ascertain the following information:

No specific laboratory tests are available. It is important to exclude other disorders by medical history and a comprehensive laboratory evaluation when indicated.

Physical Examination

Regardless of the clinical form of recurrent aphthous ulcer, ulcers are confined to the nonkeratinized mucosa of the mouth, sparing the dorsum of the tongue, the attached gingiva, and the hard palate mucosae, which are keratinized unless the patient is HIV positive. Although patients may have submandibular lymphadenopathy, fever is rare. Most patients are otherwise well. Different gradations and their findings are as follows:

Causes

Although the clinical characteristics of recurrent aphthous ulcer are well defined, the precise etiology and the pathogenesis of recurrent aphthous ulcer remain unclear. Many possibilities have been investigated. Recurrent aphthous ulcer is a multifactorial condition, and it is likely that immune-mediated destruction of the epithelium is the common factor in recurrent aphthous ulcer pathogenesis. Host risk factors associated with recurrent aphthous ulcer are described below.

Genetics

A family history of recurrent aphthous ulcers is evident in some patients. A familial connection includes a young age of onset and symptoms of increased severity. Recurrent aphthous ulcer is highly correlated in identical twins.[33, 34]

Associations between specific HLA haplotypes (eg, HLA- B51) and recurrent aphthous ulcer have been investigated. No consistent association has been demonstrated. However, in two Iranian studies, polymorphisms in an inflammasome-related gene, NLRP3, and in the promoter region for the IL6 gene were found to be significantly associated with recurrent aphthous in a small cohort of patients.[35, 36] Still, host susceptibility is clearly variable, with a polygenic inheritance pattern, and penetrance likely depends on other factors.[37]

Hematinic deficiency

In several studies, hematinic (iron, folic acid, vitamins B-6 and B-12) deficiencies were twice as common in patients with recurrent aphthous ulcers as in control subjects. As many as 20% of patients with recurrent aphthous ulcer have a hematinic deficiency, with some studies also reporting notable elevations of blood homocysteine.[16] Lower dietary intake of folate and vitamin B-12 is more common among persons with aphthous ulcers[38] and treatment with 1000 mcg/d has shown benefit in individuals regardless of serum B-12 levels.[39, 40] A small group of adolescents were shown to have reduced incidence and pain from recurrent aphthous stomatitis when given 2000 mg/d of ascorbic acid.[41] Vitamin D deficiency is also more prevalent in patients with recurrent aphthous stomatitis, although there is no correlation between vitamin D levels and a patient’s clinical course, including number of ulcers, duration of ulcers, or frequency of ulcer development.[42]

Thus, serologic workup is warranted. Hemoglobin and RBC indices are not sufficient in all cases.

Immune dysregulation

At present, no unifying theory of the immunopathogenesis of recurrent aphthous ulcer exists, but immune dysregulation may play a significant role. Cytotoxic action of lymphocytes and monocytes on the oral epithelium seems to cause the ulceration, but the trigger remains unclear. Upon histologic analysis, recurrent aphthous ulcer consists of mucosal ulcerations with mixed inflammatory cell infiltrates. T-helper cells predominate in the preulcerative and healing phases, whereas T-suppressor cells predominate in the ulcerative phase.

Other findings associated with immune dysregulation include the following:

Microbial infection

Researchers disagree about the role of microbes in the development of recurrent aphthous ulcers. Emphasis has been on a microbial agent as a primary pathogen or an antigenic stimulus. Numerous studies have failed to provide strong evidence to support the role of herpes simplex virus, human herpesvirus, varicella-zoster virus, or cytomegalovirus in the development of aphthous ulcers.[53, 54]

Recurrent aphthous ulcer formation may be a T-cell–mediated response to antigens of Streptococcus sanguis that cross-react with the mitochondrial heat shock proteins and induce oral mucosa damage. Helicobacter pylori has been detected in lesional tissue of oral ulcers, and a 2014 meta-analysis found H pylori infection was associated with an increased risk of recurrent aphthous stomatitis.[55] Still, the frequency of serum immunoglobulin G antibodies to H pylori is not increased in recurrent aphthous ulcers, and the organisms have never proven causative.[56, 57, 58, 59, 60]

Imbalances in the oral mucosal microbiome have been identified in patients with recurrent aphthous stomatitis. Although no phylum-level differences were appreciated between nonulcerated sites in these patients and healthy controls, patients with recurrent aphthous stomatitis did exhibit an increased abundance of Bacteroidales species. Further investigation is required to understand if these microbiome imbalances play a causative role in aphthous stomatitis and how diet and oral hygiene influence the oral mucosal microbiome.[61]

Approach Considerations

In 2013, Tappuni et al introduced the Ulcer Severity Score (USS) because of the lack of standardized assessment methods for aphthous stomatitis.[79] The USS incorporates six ulcer characteristics: number, size, duration, ulcer-free period, site, and pain. This scoring template may be of value to future studies assessing treatment efficacy, although at present it is not widely used. Challacombe et al suggest using the USS in combination with the Oral Health Related Quality of Life (OHR-QoL) score in order to better estimate the impact of clinically significant aphthous stomatitis on patients.[80]

Laboratory Studies

The following laboratory studies may be helpful:

Other Tests

The following procedures may be indicated if other disease is suspected:

Histologic Findings

Nonspecific ulcers with chronic mixed inflammatory cells are observed. The pseudomembrane covering of aphthae is a combination of oral bacteria and fungi, as well as necrotic keratinocytes and sloughed oral mucosa.

Approach Considerations

Many therapeutic options, with varying degrees of supporting evidence, are recommended for the treatment of aphthous stomatitis. The choice should be guided by disease severity, level of evidence, cost, and adverse effect profile. Treatment for recurrent aphthous ulcers is directed at palliation of symptoms, shortening of healing time,[83, 84] and prophylaxis against future episodes.

Of note, many of the treatments are used without research demonstrating therapeutic results specific to aphthous stomatitis. A 2012 Cochrane review of systemic treatments for aphthous stomatitis found that data from four major trials lacked methodological rigor and concluded that no single therapy could be recommended given the data currently available.[85]

 

Medical Care

Please refer to medications section for specific information regarding recommended dosage and mechanism of action.

Topical regimens may include the following:

Systemic agents may include the following:

Miscellaneous medical treatments are as follows:

Laser therapy has been reported to provide pain relief and lesion resolution for isolated lesions, but it does not affect episodic recurrence.[114, 115]

Surgical Care

No surgical treatment has been used effectively because of the recurrent nature of recurrent aphthous ulcers.[116]

Diet

An elimination diet may help control outbreaks by revealing suspected allergic stimuli that initiate oral lesions. If food exposure is thought to be the culprit, a food diary can be helpful.[117, 118, 119] Advise avoidance of salt and hot spices to prevent pain from unnecessary aphthae irritation. Some patients report aphthae after exposure to figs, pineapple, cheese, and sodium lauryl sulfate, which is found in certain toothpastes and oral rinses. In such cases, remission may be achieved by avoiding the inciting agent.

A gluten-free diet helps patients with gluten-sensitive enteropathy (celiac disease) control outbreaks of aphthae.[31]

Patients with oral lesions should avoid hard or sharp foods that may gouge existing ulcers or create new ones (Koebnerization).

Although some patients may have demonstrable hematinic deficiencies, daily multivitamin therapy does not appear to prevent recurrent aphthous stomatitis episodes.[120]

Prevention

An association between smoking and reducing the occurrence of recurrent aphthous ulcer has been reported. In one epidemiologic study, the incidence of recurrent aphthous ulcer was lower in all groups using any form of tobacco than in people not using tobacco.[121, 122] This may be dose-dependent, and the reduced incidence may be limited to heavy smokers.[123]  Tobacco may increase keratinization of the mucosa, which, in turn, may decrease the susceptibility to ulceration. Nicotine, a locally absorbed substance, may play a role in preventing aphthae. Research subjects lose the protective effect when they stop smoking and they may experience rebound ulceration. Despite this, these findings do not justify recommending the use of tobacco or nicotine to control this condition. Other, less harmful treatments are available. Nicotine replacement therapy may help ameliorate lesions that have resulted from cessation of a tobacco habit.[124]

It has been suggested that various foods and environmental triggers have a role in causing or exacerbating recurrent aphthous ulcers. As such, avoidance of these potential triggers (including pineapple, tomato, figs, cheese, and sodium lauryl sulfate) may prevent or reduce the severity of episodes.[62, 63, 64]

Although many patients with recurrent aphthous ulcers have hematinic deficiencies, multivitamins with iron have not been shown to reduce the severity of aphthae or the frequency of ulcer development.[120]

Medication Summary

Therapy for this condition is aimed at palliating symptoms, shortening healing time, and reducing the number of episodes (prophylaxis)

Prednisone (Deltasone)

Clinical Context:  Prednisone is a systemic corticosteroid for cases of severe aphthae; it is inactive and must be metabolized to the active metabolite prednisolone. Close follow-up care and monitoring are required to monitor for candidiasis and other secondary infections and adverse reactions. Prednisone is available in a 5 mg/5 mL solution.

Dexamethasone (Decadron, Dexasone)

Clinical Context:  Dexamethasone is the drug of choice for recurrent aphthous ulcers and various inflammatory diseases. It decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reducing capillary permeability. An elixir of 0.5 mg/5 mL (high potency, substituted, fluorinated) may be used.

Triamcinolone topical (Aristocort)

Clinical Context:  Topical triamcinolone is for inflammatory dermatoses responsive to steroids; it decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing capillary permeability. It is advisable when local disease is accessible to the patient. Use 0.1% gel.

Fluocinonide (Fluonex, Lidex)

Clinical Context:  Fluocinonide is a high-potency topical corticosteroid that inhibits cell proliferation; it is immunosuppressive and anti-inflammatory. It is advisable when local disease is accessible to the patient. Use 0.05% gel.

Clobetasol propionate (Temovate)

Clinical Context:  Clobetasol propionate is a class I superpotent topical steroid that suppresses mitosis and increases the synthesis of proteins that decrease inflammation and cause vasoconstriction. Use 0.05% gel.

Class Summary

Topical steroids are the first-line therapy. They are used to suppress immunologic- and inflammatory-mediated attacks resulting in ulceration. They are used to treat idiopathic and acquired autoimmune disorders.

Lidocaine anesthetic (Xylocaine)

Clinical Context:  Lidocaine anesthetic is an amide-type local anesthetic. It decreases permeability to sodium ions in neuronal membranes and inhibits depolarization, blocking the transmission of nerve impulses. Use 2% viscous solution.

Benzocaine (Americaine, Anbesol)

Clinical Context:  Benzocaine is a para-aminobenzoic acid (PABA) derivative, ester-type local anesthetic that is minimally absorbed. It inhibits neuronal membrane depolarization, blocking nerve impulses.

Class Summary

These agents locally relieve pain of recurrent aphthous ulcers.

Sucralfate (Carafate)

Clinical Context:  Sucralfate is a sulfate-aluminum complex, which coats ulcer surfaces, forming a physical barrier. In this way, it protects the ulcer surface from irritation. Some studies have reported improvement in symptomology and duration of ulcers, while other studies have found that sucralfate is not effective in the treatment of recurrent aphthous ulcers.

Bismuth subsalicylate (Kaopectate, Kaopectate Extra Strength, Maalox Total Relief)

Clinical Context:  Bismuth subsalicylate has been used to reduce pain from oral ulcers by protecting raw mucosa. It may also accelerate reepithelialization, although its mechanism of action is largely unknown. Some clinicians advise patients to include bismuth subsalicylate in mouthwash recipes along with other ingredients, such as liquid diphenhydramine.

Bioadherent oral (Gelclair)

Clinical Context:  This oral bioadherent adheres to the mucosal surface of mouth and forms a protective coating that shields exposed and overstimulated nerve endings. Ingredients include water, maltodextrin, propylene glycol, polyvinylpyrrolidone (PVP), sodium hyaluronate, potassium sorbate, sodium benzoate, hydroxy ethylcellulose, polyethylene glycol (PEG)–40, hydrogenated castor oil, disodium edetate, benzalkonium chloride, flavoring, saccharin sodium, and glycyrrhetinic acid.

Class Summary

These agents protect and bolster natural mucosal barrier.

2-Octyl cyanoacrylate

Clinical Context:  Over-the-counter formulations of cyanoacrylate (essentially Super Glue) form a waterproof occlusive barrier over ulcers.

Class Summary

These agents are indicated for topical application to hold closed easily approximated skin edges of wounds. They may be helpful in aphthous ulcers.

Colchicine (Colcrys, Mitigare)

Clinical Context:  Colchicine is an anti-inflammatory agent that inhibits microtubule polymerization.  Studies have shown that colchicine is effective in reducing pain from aphthous ulcers, as well as decreasing the frequency of ulcer formation. Adverse effects include gastrointestinal upset, such as diarrhea, and neutropenia. Use 0.6 mg thrice daily.

Montelukast (Singulair)

Clinical Context:  Montelukast sodium is an immunosuppressive agent that acts via leukotriene receptor antagonism. It blocks leukotrienes, downstream metabolic products of arachidonic acid, from binding to receptors located on neutrophils and macrophages and thereby blocks their activation, chemotaxis, and degranulation. It is reported to have equal efficacy as prednisone in the treatment of recurrent aphthous stomatitis, with fewer adverse effects.

Clofazimine (Lamprene)

Clinical Context:  Clofazimine is an immunosuppressive and anti-inflammatory agent with antibacterial properties that has shown efficacy in reducing the frequency of ulcers and symptoms in patients who continue to experience ulcers. Although its precise mechanism of action is unclear, it has been shown to accumulate in phagocytes, increase lysosomal enzyme production, and inhibit neutrophil migration.

Azathioprine (Imuran)

Clinical Context:  Azathioprine is largely converted to the active metabolites 6-mercaptopurine and 6-thioinosinic acid; it antagonizes purine metabolism and inhibits the synthesis of DNA, RNA, and proteins. It may decrease the proliferation of immune cells, lowering autoimmune activity. It may decrease the proliferation of immune cells, lowering autoimmune activity.

Thalidomide (Thalomid)

Clinical Context:  Thalidomide was the first FDA-approved therapy for recurrent aphthous ulcer. It is an immunomodulatory agent that may suppress excessive production of tumor necrosis factor (TNF)‒alpha and may down-regulate selected cell-surface adhesion molecules involved in leukocyte migration. Close follow-up, including nerve conduction studies and electromyography every 6 months, is recommended in patients using thalidomide.

Class Summary

These agents blunt immunologically mediated destruction leading to mucosal ulceration. Systemic immunosuppressants are indicated for severe and recalcitrant cases of aphthous stomatitis.

Cyclosporine (Gengraf, Neoral, Sandimmune)

Clinical Context:  Cyclosporine is a potent immunosuppressant that binds cyclophilin on lymphocytes to inhibit calcineurin and thereby prevent the production of interleukin 2. In this way, it dampens the immune response and particularly the action of T cells. Cyclosporine has been tested as a systemic agent and a topical paste with mixed reports of efficacy, but it is now most often used effectively as an oral rinse.

Amlexanox (Aphthasol)

Clinical Context:  Amlexanox is an adhesive oral paste whose mechanism of action is unknown. It appears to accelerate the healing of aphthous ulcers. Amlexanox appears as a beige-colored paste. It is a potent inhibitor of the formation and release of inflammatory mediators (histamine and leukotrienes) from mast cells, neutrophils, and mononuclear cells in in vitro studies. Amlexanox is FDA approved for the treatment of recurrent aphthous stomatitis.

Class Summary

These agents are inhibitors of the formation and/or release of inflammatory mediators.

Isotretinoin (Absorica, Amnesteem, Claravis)

Clinical Context:  Researchers have found systemic isotretinoin to be an effective therapy for recurrent aphthous ulcers. Additionally, isotretinoin (0.1% gel) has been used in the treatment of oral lichen planus with reported efficacy, and it may also be useful in the treatment of recurrent aphthous ulcers.

Tretinoin topical (Atralin, Avita, Refissa)

Clinical Context:  Tretinoin in an adhesive base (0.1%) has been used in the treatment of oral lichen planus with reported efficacy, and it may also be useful in the treatment of recurrent aphthous ulcers.

Retinoic acid

Clinical Context:  Retinoic acid in an oral base (0.05%) has been used in the treatment of oral lichen planus with reported efficacy, and it may also be useful in the treatment of recurrent aphthous ulcers.

Class Summary

Retinoids are a class of drugs closely related to vitamin A. They are used to regulate epithelial cell differentiation and have also been shown to have immunomodulatory and anti-inflammatory effects.

Chlorhexidine oral (Peridex, PerioChip, PerioGard)

Clinical Context:  Chlorhexidine gluconate is an adjunct treatment for gingival disease; it binds to negatively charged bacterial cell walls and extramicrobial complex, causing bacteriostatic and bactericidal effects. Chlorhexidine gluconate is an effective, safe, and reliable topical wash or oral mouthwash antiseptic.

Tetracycline

Clinical Context:  Tetracycline treats gram-positive and gram-negative organisms and mycoplasmal, chlamydial, and rickettsial infections. It inhibits bacterial protein synthesis by binding with 30S and possibly 50S ribosomal subunits. Use the oral suspension. It may have an anti-inflammatory in addition to antibacterial mechanism of action.

Class Summary

These agents treat inflammation of the oral mucosa caused by bacterial or fungal actions.

Pentoxifylline (Pentoxil, Trental)

Clinical Context:  Pentoxifylline inhibits the production of TNF-alpha and reduces the migration of neutrophils. Its specific action in aphthous stomatitis is unclear, but it has been shown to reduce the severity and frequency of episodes.

Class Summary

Hemorheologic agents may be beneficial in patients who do not respond to other therapies; they are not first-line treatment.

Cevimeline (Evoxac)

Clinical Context:  Cevimeline is a parasympathomimetic agent that acts via muscarinic acetylcholine receptors to induce salivation. Use cevimeline at 30 mg  orally thrice daily.

Pilocarpine (Pilocarpine PO, Salagen)

Clinical Context:  Pilocarpine is a parasympathomimetic agent that acts via muscarinic acetylcholine receptors to induce salivation. Use 5 mg, 1-2 tablets, 3-4 times per day, not to exceed 30 g/day.

Class Summary

As xerostomia may exacerbate or even contribute to the development of aphthous ulcers, treatment with agents known to increase saliva production may be of benefit to some patients.

Quercetin

Clinical Context:  Quercetin is a plant flavonoid that has been shown to stimulate gastric epithelial cell proliferation and may be used as an adjunct topical agent to shorten healing time and reduce pain.

Class Summary

These agents may be used as adjunct topical treatments to shorten healing time and reduce pain.

What is aphthous stomatitis (canker sore)?What is the pathophysiology of aphthous stomatitis (canker sore)?Where in the mucosa does aphthous stomatitis (canker sore) occur?How are aphthous stomatitis (canker sore) categorized?What are characteristics of recurrent aphthous ulcer minor (Mikulicz ulcer)?What are characteristics of recurrent aphthous ulcer major (Sutton ulcer, periadenitis mucosa necrotica recurrens)?What are characteristics of herpetiform recurrent aphthous ulcers?What is the prevalence of aphthous stomatitis (canker sore)?What is the global prevalence of aphthous stomatitis (canker sore)?How does the prevalence of aphthous stomatitis (canker sore) vary by sex?How does the prevalence of aphthous stomatitis (canker sore) vary by age?Where can patient education resources be found for aphthous stomatitis (canker sore)?What should be the focus of history in the evaluation of aphthous stomatitis (canker sore)?Which physical findings are characteristic of aphthous stomatitis (canker sore)?What causes aphthous stomatitis (canker sore)?What is the role of genetics in the etiology of aphthous stomatitis (canker sore)?What is the role of hematinic deficiency in the etiology of aphthous stomatitis (canker sore)?What is the role of immune dysregulation in the etiology of aphthous stomatitis (canker sore)?What are findings associated with immune dysregulation in patients with aphthous stomatitis (canker sore)?What is the role of microbial infection in the etiology of aphthous stomatitis (canker sore)?Which clinical conditions are considered in the differential diagnosis of aphthous stomatitis (canker sore)?What are the differential diagnoses for Aphthous Stomatitis?What is the Ulcer Severity Score (USS) for the assessment of aphthous stomatitis (canker sore)?Which lab studies are performed in the diagnosis of aphthous stomatitis (canker sore)?Which tests may be performed to differentiate aphthous stomatitis (canker sore) from other conditions?Which histologic findings suggest aphthous stomatitis (canker sore)?What is the basis for treatment selection in aphthous stomatitis (canker sore)?Which topical medications are used in the treatment of aphthous stomatitis (canker sore)?Which systemic agents are used in the treatment of aphthous stomatitis (canker sore)?What are less common medical treatment options for aphthous stomatitis (canker sore)?What is the role of laser therapy in the treatment of aphthous stomatitis (canker sore)?When is surgery indicated in the treatment of aphthous stomatitis (canker sore)?How is dietary modification used in the treatment of aphthous stomatitis (canker sore)?How are aphthous stomatitis (canker sore) prevented?What are the goals of drug treatment for aphthous stomatitis?Which medications in the drug class Ear, Eye, Nose & Throat, Herbals are used in the treatment of Aphthous Stomatitis?Which medications in the drug class Secretagogues are used in the treatment of Aphthous Stomatitis?Which medications in the drug class Hemorheologic agents are used in the treatment of Aphthous Stomatitis?Which medications in the drug class Antibacterial agents are used in the treatment of Aphthous Stomatitis?Which medications in the drug class Retinoids are used in the treatment of Aphthous Stomatitis?Which medications in the drug class Topical immunomodulators are used in the treatment of Aphthous Stomatitis?Which medications in the drug class Immunosuppressants are used in the treatment of Aphthous Stomatitis?Which medications in the drug class Topical occlusives are used in the treatment of Aphthous Stomatitis?Which medications in the drug class Coating agents are used in the treatment of Aphthous Stomatitis?Which medications in the drug class Anesthetics are used in the treatment of Aphthous Stomatitis?Which medications in the drug class Corticosteroids are used in the treatment of Aphthous Stomatitis?

Author

Ginat W Mirowski, MD, DMD, Adjunct Associate Professor, Departments of Oral Pathology, Medicine, and Radiology, Indiana University School Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Diana V Messadi, DDS, MMSc, DMSc, Professor of Dentistry, Associate Dean for Education and Faculty Development, Chair, Section of Oral Medicine and Orofacial Pain, University of California, Los Angeles, School of Dentistry

Disclosure: Nothing to disclose.

Heather C Rosengard, MPH, Johns Hopkins University School of Medicine

Disclosure: Nothing to disclose.

Specialty Editors

Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Disclosure: Nothing to disclose.

Warren R Heymann, MD, Head, Division of Dermatology, Professor, Department of Internal Medicine, Rutgers New Jersey Medical School

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD, Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

Disclosure: Received income in an amount equal to or greater than $250 from: Elsevier; WebMD.

Additional Contributors

Christy L Nebesio, MD, Dermatologist

Disclosure: Nothing to disclose.

David P Fivenson, MD, Associate Director, St Joseph Mercy Hospital Dermatology Program, Ann Arbor, Michigan

Disclosure: Nothing to disclose.

Jeffrey M Casiglia, DMD, DMSc, Lecturer, Harvard School of Dental Medicine; Private Practice, Salem, Massachusetts

Disclosure: Nothing to disclose.

References

  1. Crivelli MR, Aguas S, Adler I, Quarracino C, Bazerque P. Influence of socioeconomic status on oral mucosa lesion prevalence in schoolchildren. Community Dent Oral Epidemiol. 1988 Feb. 16(1):58-60. [View Abstract]
  2. Shulman JD. An exploration of point, annual, and lifetime prevalence in characterizing recurrent aphthous stomatitis in USA children and youths. J Oral Pathol Med. 2004 Oct. 33 (9):558-66. [View Abstract]
  3. Axéll T, Henricsson V. The occurrence of recurrent aphthous ulcers in an adult Swedish population. Acta Odontol Scand. 1985 May. 43(2):121-5. [View Abstract]
  4. Embil JA, Stephens RG, Manuel FR. Prevalence of recurrent herpes labialis and aphthous ulcers among young adults on six continents. Can Med Assoc J. 1975 Oct 4. 113 (7):627-30. [View Abstract]
  5. Axéll T. A prevalence study of oral mucosal lesions in an adult Swedish population. Odontol Revy Suppl. 1976. 36:1-103. [View Abstract]
  6. Robledo-Sierra J, Mattsson U, Svedensten T, Jontell M. The morbidity of oral mucosal lesions in an adult Swedish population. Med Oral Patol Oral Cir Bucal. 2013 Sep 1. 18 (5):e766-72. [View Abstract]
  7. Cebeci AR, Gülşahi A, Kamburoglu K, Orhan BK, Oztaş B. Prevalence and distribution of oral mucosal lesions in an adult Turkish population. Med Oral Patol Oral Cir Bucal. 2009 Jun 1. 14 (6):E272-7. [View Abstract]
  8. Mumcu G, Cimilli H, Sur H, Hayran O, Atalay T. Prevalence and distribution of oral lesions: a cross-sectional study in Turkey. Oral Dis. 2005 Mar. 11 (2):81-7. [View Abstract]
  9. Safadi RA. Prevalence of recurrent aphthous ulceration in Jordanian dental patients. BMC Oral Health. 2009 Nov 22. 9:31. [View Abstract]
  10. Davatchi F, Tehrani-Banihashemi A, Jamshidi AR, et al. The prevalence of oral aphthosis in a normal population in Iran: a WHO-ILAR COPCORD study. Arch Iran Med. 2008 Mar. 11 (2):207-9. [View Abstract]
  11. Abdullah MJ. Prevalence of recurrent aphthous ulceration experience in patients attending Piramird dental speciality in Sulaimani City. J Clin Exp Dent. 2013 Apr 1. 5 (2):e89-94. [View Abstract]
  12. Bhatnagar P, Rai S, Bhatnagar G, Kaur M, Goel S, Prabhat M. Prevalence study of oral mucosal lesions, mucosal variants, and treatment required for patients reporting to a dental school in North India: In accordance with WHO guidelines. J Family Community Med. 2013 Jan. 20 (1):41-8. [View Abstract]
  13. Thangadurai M, Andamuthu Y, Srinivasan A, Abikshyeet P, Kumar SJS, Vilvanathan V. Prevalence and family history of recurrent aphthous stomatitis among the students of a dental institution in south India. J Indian Acad Dental Specialist Researchers. 2014. 1(2):53-55.
  14. Field EA, Brookes V, Tyldesley WR. Recurrent aphthous ulceration in children--a review. Int J Paediatr Dent. 1992 Apr. 2 (1):1-10. [View Abstract]
  15. Lopez-Jornet P, Camacho-Alonso F, Martos N. Hematological study of patients with aphthous stomatitis. Int J Dermatol. 2014 Feb. 53 (2):159-63. [View Abstract]
  16. Sun A, Chen HM, Cheng SJ, Wang YP, Chang JY, Wu YC, et al. Significant association of deficiencies of hemoglobin, iron, vitamin B12, and folic acid and high homocysteine level with recurrent aphthous stomatitis. J Oral Pathol Med. 2015 Apr. 44 (4):300-5. [View Abstract]
  17. Gallo Cde B, Mimura MA, Sugaya NN. Psychological stress and recurrent aphthous stomatitis. Clinics (Sao Paulo). 2009. 64(7):645-8. [View Abstract]
  18. Huling LB, Baccaglini L, Choquette L, Feinn RS, Lalla RV. Effect of stressful life events on the onset and duration of recurrent aphthous stomatitis. J Oral Pathol Med. 2012 Feb. 41(2):149-52. [View Abstract]
  19. MacPhail LA, Greenspan D, Feigal DW, Lennette ET, Greenspan JS. Recurrent aphthous ulcers in association with HIV infection. Description of ulcer types and analysis of T-lymphocyte subsets. Oral Surg Oral Med Oral Pathol. 1991 Jun. 71(6):678-83. [View Abstract]
  20. Burton-Kee JE, Mowbray JF, Lehner T. Different cross-reacting circulating immune complexes in Behçet's syndrome and recurrent oral ulcers. J Lab Clin Med. 1981 Apr. 97(4):559-67. [View Abstract]
  21. Eglin RP, Lehner T, Subak-Sharpe JH. Detection of RNA complementary to herpes-simplex virus in mononuclear cells from patients with Behçet's syndrome and recurrent oral ulcers. Lancet. 1982 Dec 18. 2(8312):1356-61. [View Abstract]
  22. Jorizzo JL. Behcet's disease. Freedberg IM, Eisen AZ, Wolff K, et al, eds. Dermatology in General Medicine. New York: McGraw-Hill Professional; 1999. Vol 2: 2161-5.
  23. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med. 1999 Oct 21. 341(17):1284-91. [View Abstract]
  24. Studd M, McCance DJ, Lehner T. Detection of HSV-1 DNA in patients with Behçet's syndrome and in patients with recurrent oral ulcers by the polymerase chain reaction. J Med Microbiol. 1991 Jan. 34(1):39-43. [View Abstract]
  25. Adisen E, Aral A, Aybay C, Gürer MA. Salivary epidermal growth factor levels in Behçet's disease and recurrent aphthous stomatitis. Dermatology. 2008. 217(3):235-40. [View Abstract]
  26. Hazzaa HH, Rashwan WA, Attia EA. IL-18 gene polymorphisms in aphthous stomatitis vs. Behçet's disease in a cohort of Egyptian patients. J Oral Pathol Med. 2014 Nov. 43 (10):746-53. [View Abstract]
  27. Ferguson MM, Wray D, Carmichael HA, Russell RI, Lee FD. Coeliac disease associated with recurrent aphthae. Gut. 1980 Mar. 21(3):223-6. [View Abstract]
  28. Ferguson R, Basu MK, Asquith P, Cooke WT. Jejunal mucosal abnormalities in patients with recurrent aphthous ulceration. Br Med J. 1976 Jan 3. 1(6000):11-13. [View Abstract]
  29. Wray D. Gluten-sensitive recurrent aphthous stomatitis. Dig Dis Sci. 1981 Aug. 26(8):737-40. [View Abstract]
  30. Yasar S, Yasar B, Abut E, Asiran Serdar Z. Clinical importance of celiac disease in patients with recurrent aphthous stomatitis. Turk J Gastroenterol. 2012 Feb. 23(1):14-8. [View Abstract]
  31. de Carvalho FK, de Queiroz AM, Bezerra da Silva RA, Sawamura R, Bachmann L, Bezerra da Silva LA, et al. Oral aspects in celiac disease children: clinical and dental enamel chemical evaluation. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Jun. 119 (6):636-43. [View Abstract]
  32. Zunt S. Severe/frequent recurrent aphthous ulcers and salivary flow rates. Oral Surg, Oral Med, Oral Pathol and Oral Rad. 2004. 98(2):
  33. Miller MF, Garfunkel AA, Ram C, Ship II. Inheritance patterns in recurrent aphthous ulcers: twin and pedigree data. Oral Surg Oral Med Oral Pathol. 1977 Jun. 43(6):886-91. [View Abstract]
  34. Slebioda Z, Szponar E, Kowalska A. Recurrent aphthous stomatitis: genetic aspects of etiology. Postepy Dermatol Alergol. 2013 Apr. 30 (2):96-102. [View Abstract]
  35. Bidoki AZ, Harsini S, Sadr M, Soltani S, Mohammadzadeh M, Najafi S, et al. NLRP3 gene polymorphisms in Iranian patients with recurrent aphthous stomatitis. J Oral Pathol Med. 2015 May 28. [View Abstract]
  36. Najafi S, Yousefi H, Mohammadzadeh M, Bidoki AZ, Firouze Moqadam I, Farhadi E, et al. Association study of interleukin-1 family and interleukin-6 gene single nucleotide polymorphisms in recurrent aphthous stomatitis. Int J Immunogenet. 2015 Dec. 42 (6):428-31. [View Abstract]
  37. Wilhelmsen NS, Weber R, Monteiro F, Kalil J, Miziara ID. Correlation between histocompatibility antigens and recurrent aphthous stomatitis in the Brazilian population. Braz J Otorhinolaryngol. 2009 May-Jun. 75(3):426-31. [View Abstract]
  38. Kozlak ST, Walsh SJ, Lalla RV. Reduced dietary intake of vitamin B12 and folate in patients with recurrent aphthous stomatitis. J Oral Pathol Med. 2010 Feb 7. [View Abstract]
  39. Carrozzo M. Vitamin B12 for the treatment of recurrent aphthous stomatitis. Evid Based Dent. 2009. 10(4):114-5. [View Abstract]
  40. Baccaglini L, Lalla RV, Bruce AJ, Sartori-Valinotti JC, Latortue MC, Carrozzo M, et al. Urban legends: recurrent aphthous stomatitis. Oral Dis. 2011 Nov. 17(8):755-70. [View Abstract]
  41. Yasui K, Kurata T, Yashiro M, Tsuge M, Ohtsuki S, Morishima T. The effect of ascorbate on minor recurrent aphthous stomatitis. Acta Paediatr. 2009 Dec 10. [View Abstract]
  42. Khabbazi A, Ghorbanihaghjo A, Fanood F, Kolahi S, Hajialiloo M, Rashtchizadeh N. A comparative study of vitamin D serum levels in patients with recurrent aphthous stomatitis. Egyptian Rheumatol. 2015. 37(3):133-37.
  43. Sun A, Chu CT, Wu YC, Yuan JH. Mechanisms of depressed natural killer cell activity in recurrent aphthous ulcers. Clin Immunol Immunopathol. 1991 Jul. 60(1):83-92. [View Abstract]
  44. Lewkowicz N, Kur B, Kurnatowska A, Tchorzewski H, Lewkowicz P. Expression of Th1/Th2/Th3/Th17-related genes in recurrent aphthous ulcers. Arch Immunol Ther Exp (Warsz). 2011 Oct. 59(5):399-406. [View Abstract]
  45. Taylor LJ, Bagg J, Walker DM, Peters TJ. Increased production of tumour necrosis factor by peripheral blood leukocytes in patients with recurrent oral aphthous ulceration. J Oral Pathol Med. 1992 Jan. 21(1):21-5. [View Abstract]
  46. Hasan A, Childerstone A, Pervin K, et al. Recognition of a unique peptide epitope of the mycobacterial and human heat shock protein 65-60 antigen by T cells of patients with recurrent oral ulcers. Clin Exp Immunol. 1995 Mar. 99(3):392-7. [View Abstract]
  47. Miyamoto NT Jr, Borra RC, Abreu M, Weckx LL, Franco M. Immune-expression of HSP27 and IL-10 in recurrent aphthous ulceration. J Oral Pathol Med. 2008 Sep. 37(8):462-7. [View Abstract]
  48. Albanidou-Farmaki E, Poulopoulos AK, Epivatianos A, Farmakis K, Karamouzis M, Antoniades D. Increased anxiety level and high salivary and serum cortisol concentrations in patients with recurrent aphthous stomatitis. Tohoku J Exp Med. 2008 Apr. 214(4):291-6. [View Abstract]
  49. Borra RC, de Mesquita Barros F, de Andrade Lotufo M, Villanova FE, Andrade PM. Toll-like receptor activity in recurrent aphthous ulceration. J Oral Pathol Med. 2009 Mar. 38(3):289-98. [View Abstract]
  50. Arikan S, Durusoy C, Akalin N, Haberal A, Seckin D. Oxidant/antioxidant status in recurrent aphthous stomatitis. Oral Dis. 2009 Oct. 15(7):512-5. [View Abstract]
  51. Bagan J, Saez G, Tormos C, Gavalda C, Sanchis JM, Bagan L, et al. Oxidative stress and recurrent aphthous stomatitis. Clin Oral Investig. 2014 Nov. 18 (8):1919-23. [View Abstract]
  52. Ozdemir IY, Calka O, Karadag AS, Akdeniz N, Ozturk M. Thyroid autoimmunity associated with recurrent aphthous stomatitis. J Eur Acad Dermatol Venereol. 2012 Feb. 26(2):226-30. [View Abstract]
  53. Ghodratnama F, Wray D, Bagg J. Detection of serum antibodies against cytomegalovirus, varicella zoster virus and human herpesvirus 6 in patients with recurrent aphthous stomatitis. J Oral Pathol Med. 1999 Jan. 28(1):12-5. [View Abstract]
  54. Pedersen A, Hornsleth A. Recurrent aphthous ulceration: a possible clinical manifestation of reactivation of varicella zoster or cytomegalovirus infection. J Oral Pathol Med. 1993 Feb. 22(2):64-8. [View Abstract]
  55. Li L, Gu H, Zhang G. Association between recurrent aphthous stomatitis and Helicobacter pylori infection: a meta-analysis. Clin Oral Investig. 2014 Jul. 18 (6):1553-60. [View Abstract]
  56. Albanidou-Farmaki E, Giannoulis L, Markopoulos A, et al. Outcome following treatment for Helicobacter pylori in patients with recurrent aphthous stomatitis. Oral Dis. 2005 Jan. 11(1):22-6. [View Abstract]
  57. Birek C, Grandhi R, McNeill K, Singer D, Ficarra G, Bowden G. Detection of Helicobacter pylori in oral aphthous ulcers. J Oral Pathol Med. 1999 May. 28(5):197-203. [View Abstract]
  58. Elsheikh MN, Mahfouz ME. Prevalence of Helicobacter pylori DNA in recurrent aphthous ulcerations in mucosa-associated lymphoid tissues of the pharynx. Arch Otolaryngol Head Neck Surg. 2005 Sep. 131(9):804-8. [View Abstract]
  59. Mansour-Ghanaei F, Asmar M, Bagherzadeh AH, Ekbataninezhad S. Helicobacter pylori infection in oral lesions of patients with recurrent aphthous stomatitis. Med Sci Monit. 2005 Dec. 11(12):CR576-9. [View Abstract]
  60. Porter SR, Barker GR, Scully C, Macfarlane G, Bain L. Serum IgG antibodies to Helicobacter pylori in patients with recurrent aphthous stomatitis and other oral disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Mar. 83(3):325-8. [View Abstract]
  61. Hijazi K, Lowe T, Meharg C, Berry SH, Foley J, Hold GL. Mucosal microbiome in patients with recurrent aphthous stomatitis. J Dent Res. 2015 Mar. 94 (3 Suppl):87S-94S. [View Abstract]
  62. Hay KD, Reade PC. The use of an elimination diet in the treatment of recurrent aphthous ulceration of the oral cavity. Oral Surg Oral Med Oral Pathol. 1984 May. 57 (5):504-7. [View Abstract]
  63. Shim YJ, Choi JH, Ahn HJ, Kwon JS. Effect of sodium lauryl sulfate on recurrent aphthous stomatitis: a randomized controlled clinical trial. Oral Dis. 2012 Oct. 18 (7):655-60. [View Abstract]
  64. Herlofson BB, Barkvoll P. Sodium lauryl sulfate and recurrent aphthous ulcers. A preliminary study. Acta Odontol Scand. 1994 Oct. 52 (5):257-9. [View Abstract]
  65. Hasan AA, Ciancio S. Association between ingestion of nonsteroidal anti-inflammatory drugs and the emergence of aphthous-like ulcers. J Int Acad Periodontol. 2009 Jan. 11(1):155-9. [View Abstract]
  66. Scully C, Gorsky M, Lozada-Nur F. The diagnosis and management of recurrent aphthous stomatitis: a consensus approach. J Am Dent Assoc. 2003 Feb. 134 (2):200-7. [View Abstract]
  67. Samaranayake LPK, Cheung L. Samaranayake YH. Candidiasis and other fungal diseases of the mouth. Dermatol Ther. 2001. 15:251-69.
  68. Abahussein O. Ulceration in Rheumatic Disease. Matucci-Cerinic M, Furst D, Fiorentino E, eds. Skin Manifestations in Rheumatic Disease. 1st ed. New York, NY: Springer-Verlag; 2014. 63-70.
  69. Daley TD, Armstrong JE. Oral manifestations of gastrointestinal diseases. Can J Gastroenterol. 2007 Apr. 21 (4):241-4. [View Abstract]
  70. Cohen PR. Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007 Jul 26. 2:34. [View Abstract]
  71. Boxer L, Dale DC. Neutropenia: causes and consequences. Semin Hematol. 2002 Apr. 39 (2):75-81. [View Abstract]
  72. Padeh S, Stoffman N, Berkun Y. Periodic fever accompanied by aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA syndrome) in adults. Isr Med Assoc J. 2008 May. 10(5):358-60. [View Abstract]
  73. Cantarini L, Vitale A, Bartolomei B, Galeazzi M, Rigante D. Diagnosis of PFAPA syndrome applied to a cohort of 17 adults with unexplained recurrent fevers. Clin Exp Rheumatol. 2012 Mar-Apr. 30(2):269-71. [View Abstract]
  74. Imai H, Motegi M, Mizuki N, Ohtani H, Komatsuda A, Hamai K, et al. Mouth and genital ulcers with inflamed cartilage (MAGIC syndrome): a case report and literature review. Am J Med Sci. 1997 Nov. 314 (5):330-2. [View Abstract]
  75. Ramírez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, Anaya-Saavedra G, González-Ramírez I, Ponce-de-León S. The Changing Clinical Spectrum of Human Immunodeficiency Virus (HIV)-Related Oral Lesions in 1,000 Consecutive Patients: A 12-Year Study in a Referral Center in Mexico. Medicine (Baltimore). 2003 Jan. 82 (1):39-50. [View Abstract]
  76. Kimura S, Kuroda J, Akaogi T, Hayashi H, Kobayashi Y, Kondo M. Trisomy 8 involved in myelodysplastic syndromes as a risk factor for intestinal ulcers and thrombosis--Behçet's syndrome. Leuk Lymphoma. 2001 Jun. 42 (1-2):115-21. [View Abstract]
  77. Davatchi F. Diagnosis/Classification Criteria for Behcet's Disease. Patholog Res Int. 2012. 2012:607921. [View Abstract]
  78. O'Neill TW, Rigby AS, Silman AJ, Barnes C. Validation of the International Study Group criteria for Behçet's disease. Br J Rheumatol. 1994 Feb. 33 (2):115-7. [View Abstract]
  79. Tappuni AR, Kovacevic T, Shirlaw PJ, Challacombe SJ. Clinical assessment of disease severity in recurrent aphthous stomatitis. J Oral Pathol Med. 2013 Sep. 42 (8):635-41. [View Abstract]
  80. Challacombe SJ, Alsahaf S, Tappuni A. Recurrent Aphthous Stomatitis: Towards Evidence-Based Treatment?. Curr Oral Health Rep. 2015. 2:158-67.
  81. Ekiz O, Balta I, Sen BB, Rifaioglu EN, Ergin C, Balta S, et al. Mean platelet volume in recurrent aphthous stomatitis and Behçet disease. Angiology. 2014 Feb. 65 (2):161-5. [View Abstract]
  82. Rogers RS 3rd, Hutton KP. Screening for haematinic deficiencies in patients with recurrent aphthous stomatitis. Australas J Dermatol. 1986 Dec. 27(3):98-103. [View Abstract]
  83. Alidaee MR, Taheri A, Mansoori P, Ghodsi SZ. Silver nitrate cautery in aphthous stomatitis: a randomized controlled trial. Br J Dermatol. 2005 Sep. 153(3):521-5. [View Abstract]
  84. Brice SL. Clinical evaluation of the use of low-intensity ultrasound in the treatment of recurrent aphthous stomatitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Jan. 83(1):14-20. [View Abstract]
  85. Brocklehurst P, Tickle M, Glenny AM, Lewis MA, Pemberton MN, Taylor J, et al. Systemic interventions for recurrent aphthous stomatitis (mouth ulcers). Cochrane Database Syst Rev. 2012 Sep 12. 9:CD005411. [View Abstract]
  86. Liu C, Zhou Z, Liu G, Wang Q, Chen J, Wang L, et al. Efficacy and safety of dexamethasone ointment on recurrent aphthous ulceration. Am J Med. 2012 Mar. 125 (3):292-301. [View Abstract]
  87. Meng W, Dong Y, Liu J, Wang Z, Zhong X, Chen R, et al. A clinical evaluation of amlexanox oral adhesive pellicles in the treatment of recurrent aphthous stomatitis and comparison with amlexanox oral tablets: a randomized, placebo controlled, blinded, multicenter clinical trial. Trials. 2009 May 6. 10:30. [View Abstract]
  88. Khandwala A, Van Inwegen RG, Charney MR, Alfano MC. 5% amlexanox oral paste, a new treatment for recurrent minor aphthous ulcers: II. Pharmacokinetics and demonstration of clinical safety. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Feb. 83 (2):231-8. [View Abstract]
  89. Bonitsis NG, Altenburg A, Krause L, Stache T, Zouboulis CC. Current concepts in the treatment of Adamantadies-Behçet’s disease. Drugs Future. 2009. 34:749–63.
  90. Chavan M, Jain H, Diwan N, Khedkar S, Shete A, Durkar S. Recurrent aphthous stomatitis: a review. J Oral Pathol Med. 2012 Sep. 41 (8):577-83. [View Abstract]
  91. Altenburg A, Abdel-Naser MB, Seeber H, Abdallah M, Zouboulis CC. Practical aspects of management of recurrent aphthous stomatitis. J Eur Acad Dermatol Venereol. 2007 Sep. 21 (8):1019-26. [View Abstract]
  92. Elad S, Epstein JB, von Bültzingslöwen I, Drucker S, Tzach R, Yarom N. Topical immunomodulators for management of oral mucosal conditions, a systematic review; Part II: miscellaneous agents. Expert Opin Emerg Drugs. 2011 Mar. 16 (1):183-202. [View Abstract]
  93. Belenguer-Guallar I, Jiménez-Soriano Y, Claramunt-Lozano A. Treatment of recurrent aphthous stomatitis. A literature review. J Clin Exp Dent. 2014 Apr. 6 (2):e168-74. [View Abstract]
  94. Sharquie KE, Helmi RM, Noaimi AA, Kadhom AA, Al-Hayani RK. Therapeutic role of isotretinoin in the management of recurrent aphthous stomatitis (Single-Blind Controlled Therapeutic Study). J Cosmetics Dermatological Sciences and Applications. 2015. 5:15-21.
  95. Gorsky M, Epstein J, Rabenstein S, Elishoov H, Yarom N. Topical minocycline and tetracycline rinses in treatment of recurrent aphthous stomatitis: a randomized cross-over study. Dermatol Online J. 2007 May 1. 13 (2):1. [View Abstract]
  96. Clemente Rodríguez de Rivera E, Rodríguez de Rivera Campillo E, E. Jané Salas, Albuquerque R, López JL. O10364 Effectiveness of Bexident Post in the treatment of recurrent aphthous stomatitis. Oral Surg Oral Med Oral Pathol Oral Rad. 2014. 117(5):e382.
  97. Descroix V, Coudert AE, Vigé A, Durand JP, Toupenay S, Molla M, et al. Efficacy of topical 1% lidocaine in the symptomatic treatment of pain associated with oral mucosal trauma or minor oral aphthous ulcer: a randomized, double-blind, placebo-controlled, parallel-group, single-dose study. J Orofac Pain. 2011 Fall. 25 (4):327-32. [View Abstract]
  98. Buchsel PC. Polyvinylpyrrolidone-sodium hyaluronate gel (Gelclair): a bioadherent oral gel for the treatment of oral mucositis and other painful oral lesions. Expert Opin Drug Metab Toxicol. 2008 Nov. 4 (11):1449-54. [View Abstract]
  99. Ludlow JB, Kutcher MJ, Samuelson A. Intraoral digital imaging documenting recurrent aphthous ulcer healing in 2-octyl cyanoacrylate versus sham-treated lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Apr. 89 (4):425-31. [View Abstract]
  100. Campisi G, Spadari F, Salvato A. [Sucralfate in odontostomatology. Clinical experience]. Minerva Stomatol. 1997 Jun. 46 (6):297-305. [View Abstract]
  101. Ricer RE. Sucralfate vs. placebo for the treatment of aphthous ulcers: a double-blinded prospective clinical trial. Fam Pract Res J. 1989 Fall-Winter. 9 (1):33-41. [View Abstract]
  102. Halaszynski T. Management of Oral Ulcers and Burning Mouth Syndrome. Vadivelu N, Vadivelu A, Kaye AD, eds. Orofacial Pain: A Clinician’s Guide. Cham, Switzerland: Springer; 2014. 103-14.
  103. Pinto A, Lindemeyer RG, Sollecito TP. The PFAPA syndrome in oral medicine: differential diagnosis and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Jul. 102 (1):35-9. [View Abstract]
  104. Femiano F, Buonaiuto C, Gombos F, Lanza A, Cirillo N. Pilot study on recurrent aphthous stomatitis (RAS): a randomized placebo-controlled trial for the comparative therapeutic effects of systemic prednisone and systemic montelukast in subjects unresponsive to topical therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Mar. 109 (3):402-7. [View Abstract]
  105. Katz J, Langevitz P, Shemer J, Barak S, Livneh A. Prevention of recurrent aphthous stomatitis with colchicine: an open trial. J Am Acad Dermatol. 1994 Sep. 31 (3 Pt 1):459-61. [View Abstract]
  106. Dixon AJ, Wall GC. Probable colchicine-induced neutropenia not related to intentional overdose. Ann Pharmacother. 2001 Feb. 35 (2):192-5. [View Abstract]
  107. Brown RS, Bottomley WK. Combination immunosuppressant and topical steroid therapy for treatment of recurrent major aphthae. A case report. Oral Surg Oral Med Oral Pathol. 1990 Jan. 69 (1):42-4. [View Abstract]
  108. de Abreu MA, Hirata CH, Pimentel DR, Weckx LL. Treatment of recurrent aphthous stomatitis with clofazimine. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Nov. 108(5):714-21. [View Abstract]
  109. Femiano F, Gombos F, Scully C. Recurrent aphthous stomatitis unresponsive to topical corticosteroids: a study of the comparative therapeutic effects of systemic prednisone and systemic sulodexide. Int J Dermatol. 2003 May. 42 (5):394-7. [View Abstract]
  110. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997 May 22. 336 (21):1487-93. [View Abstract]
  111. Thornhill MH, Baccaglini L, Theaker E, Pemberton MN. A randomized, double-blind, placebo-controlled trial of pentoxifylline for the treatment of recurrent aphthous stomatitis. Arch Dermatol. 2007 Apr. 143(4):463-70. [View Abstract]
  112. Hamdy AA, Ibrahem MA. Management of aphthous ulceration with topical quercetin: a randomized clinical trial. J Contemp Dent Pract. 2010 Jul 1. 11 (4):E009-16. [View Abstract]
  113. Mostafa AAE, Ibrahem MAE. Management of aphthous ulceration with topical quercetin. Cairo Dental J. 2009. 25(1):
  114. Albrektson M, Hedström L, Bergh H. Recurrent aphthous stomatitis and pain management with low-level laser therapy: a randomized controlled trial. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 May. 117 (5):590-4. [View Abstract]
  115. Demetriades N, Hanford H, Laskarides C. General manifestations of Behçet's syndrome and the success of CO2-laser as treatment for oral lesions: a review of the literature and case presentation. J Mass Dent Soc. 2009 Fall. 58(3):24-7. [View Abstract]
  116. Arikan OK, Birol A, Tuncez F, Erkek E, Koc C. A prospective randomized controlled trial to determine if cryotherapy can reduce the pain of patients with minor form of recurrent aphthous stomatitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Jan. 101(1):e1-5. [View Abstract]
  117. Eversole LR, Shopper TP, Chambers DW. Effects of suspected foodstuff challenging agents in the etiology of recurrent aphthous stomatitis. Oral Surg Oral Med Oral Pathol. 1982 Jul. 54(1):33-8. [View Abstract]
  118. Hay KD, Reade PC. The use of an elimination diet in the treatment of recurrent aphthous ulceration of the oral cavity. Oral Surg Oral Med Oral Pathol. 1984 May. 57(5):504-7. [View Abstract]
  119. Wright A, Ryan FP, Willingham SE, et al. Food allergy or intolerance in severe recurrent aphthous ulceration of the mouth. Br Med J (Clin Res Ed). 1986 May 10. 292(6530):1237-8. [View Abstract]
  120. Lalla RV, Choquette LE, Feinn RS, Zawistowski H, Latortue MC, Kelly ET, et al. Multivitamin therapy for recurrent aphthous stomatitis: a randomized, double-masked, placebo-controlled trial. J Am Dent Assoc. 2012 Apr. 143(4):370-6. [View Abstract]
  121. Axell T, Henricsson V. Association between recurrent aphthous ulcers and tobacco habits. Scand J Dent Res. 1985 Jun. 93(3):239-42. [View Abstract]
  122. Bittoun R. Recurrent aphthous ulcers and nicotine. Med J Aust. 1991 Apr 1. 154(7):471-2. [View Abstract]
  123. Sawair FA. Does smoking really protect from recurrent aphthous stomatitis?. Ther Clin Risk Manag. 2010 Nov 22. 6:573-7. [View Abstract]
  124. Hill SC, Stavrakoglou A, Coutts IR. Nicotine replacement therapy as a treatment for complex aphthosis. J Dermatolog Treat. 2009 Oct 13. [View Abstract]

Minor aphthous ulcer: Small superficial oval erosions with yellow pseudomembrane and an erythematous border are evident on the labial aspect of the left lower lip.

Major aphthous ulcer: Large oval ulcer with white pseudomembrane and raised red border located on the right upper labial mucosa adjacent to the buccal commissure. Note the irregular margin so typical in major aphthae.

Herpetiform aphthous ulcer: Grouped and single tiny white to yellow ulcers scattered on the labial mucosa and on the ventral aspect of the tongue.

Minor aphthous ulcer: Small superficial oval erosions with yellow pseudomembrane and an erythematous border are evident on the labial aspect of the left lower lip.

Major aphthous ulcer: Large oval ulcer with white pseudomembrane and raised red border located on the right upper labial mucosa adjacent to the buccal commissure. Note the irregular margin so typical in major aphthae.

Herpetiform aphthous ulcer: Grouped and single tiny white to yellow ulcers scattered on the labial mucosa and on the ventral aspect of the tongue.

Minor aphthous ulcer: Small superficial oval erosions with yellow pseudomembrane and an erythematous border are evident on the labial aspect of the left lower lip.

Major aphthous ulcer: Large oval ulcer with white pseudomembrane and raised red border located on the right upper labial mucosa adjacent to the buccal commissure. Note the irregular margin so typical in major aphthae.

Herpetiform aphthous ulcer: Grouped and single tiny white to yellow ulcers scattered on the labial mucosa and on the ventral aspect of the tongue.